David I Stirling
Overview
Explore the profile of David I Stirling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
615
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zou J, Jones R, Wang H, Kuiatse I, Shirazi F, Manasanch E, et al.
J Mol Med (Berl)
. 2020 Jul;
98(8):1161-1173.
PMID: 32632752
Small molecules targeting the cereblon-containing E3 ubiquitin ligase including thalidomide, lenalidomide, and pomalidomide modulate turnover of downstream client proteins and demonstrate pre-clinical and clinical anti-myeloma activity. Different drugs that engage...
2.
Vu H, Miller W, OConnor S, He M, Schafer P, Payvandi F, et al.
J Surg Res
. 2009 Sep;
164(1):116-25.
PMID: 19726061
Introduction: CC-5079, a small molecule inhibitor of tubulin polymerization and phosphodiesterase-4 activity, was evaluated for antiangiogenic and antitumor activities. Materials And Methods: First, CC-5079 in vitro activity on human umbilical...
3.
Lu L, Payvandi F, Wu L, Zhang L, Hariri R, Man H, et al.
Microvasc Res
. 2008 Sep;
77(2):78-86.
PMID: 18805433
Lenalidomide (Revlimid) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del 5q cytogenetic abnormality with or without...
4.
Mangiameli D, Blansfield J, Kachala S, Lorang D, Schafer P, Muller G, et al.
J Transl Med
. 2007 Jul;
5:38.
PMID: 17640369
Background: Ocular melanoma is the leading intraocular malignancy. There is no effective treatment for metastatic ocular melanoma. We sought a treatment targeting the tumor microenvironment as well as the tumor...
5.
Christian M, Laskin O, Sharper V, Hoberman A, Stirling D, Latriano L
Birth Defects Res B Dev Reprod Toxicol
. 2007 Jun;
80(3):188-207.
PMID: 17570132
Background: Lenalidomide, a thalidomide analog, is indicated for treatment of patients with deletion-5q myelodysplastic syndromes or multiple myeloma. NZW rabbits were used because of sensitivity to thalidomide's teratogenicity. Methods: Range-finding...
6.
Gandhi A, Kang J, Naziruddin S, Parton A, Schafer P, Stirling D
Leuk Res
. 2006 Feb;
30(7):849-58.
PMID: 16494942
Lenalidomide (Revlimid, CC-5013) belongs to a line of compounds known as immunomodulatory drugs (IMiDs) that are under clinical investigation in hematopoietic and solid tumor cancers. Lenalidomide efficacy has been reported...
7.
Zhang L, Wu L, Raymon H, Chen R, Corral L, Shirley M, et al.
Cancer Res
. 2006 Jan;
66(2):951-9.
PMID: 16424030
We have found that the synthetic compound CC-5079 potently inhibits cancer cell growth in vitro and in vivo by a novel combination of molecular mechanisms. CC-5079 inhibits proliferation of cancer...
8.
Payvandi F, Wu L, Naziruddin S, Haley M, Parton A, Schafer P, et al.
J Interferon Cytokine Res
. 2005 Oct;
25(10):604-16.
PMID: 16241859
Immunomodulatory drugs (IMiDs) are orally available small molecules that potently inhibit tumor necrosis factor-alpha (TNF-alpha) production by lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells (HuPBMCs) but enhance secretion of such...
9.
Teo S, Stirling D, Zeldis J
Drug Discov Today
. 2005 Feb;
10(2):107-14.
PMID: 15718159
Thalidomide and its immunomodulatory analogues have numerous effects on the body's immune system, including potential anti-cancer and anti-inflammatory activities. Thalidomide is currently used experimentally to treat various cancers, dermatological, neurological...
10.
Payvandi F, Wu L, Haley M, Schafer P, Zhang L, Chen R, et al.
Cell Immunol
. 2004 Dec;
230(2):81-8.
PMID: 15598423
Immunomodulatory drugs (IMiDs) are potent inhibitors of TNF-alpha and IL-1beta and elevators of IL-10 production in LPS-stimulated human PBMC. They are currently in clinical trials for various diseases, including multiple...